CYTOKINETICS INC 4

Director-level insider Nancy Wysenski received an equity award of 75 shares of Cytokinetics Inc. common stock valued at roughly $6,200 as part of an equity in lieu of cash retainer program.

On July 15, 2026, insider Nancy Wysenski of Cytokinetics Inc. received a fully vested grant of 75 shares of common stock under the company’s Equity in Lieu of Cash Retainer Program at an implied price of $82.62 per share, an approximate value of $6,197. Following this equity award, her direct ownership increased to 33,992 shares of Cytokinetics common stock, with an estimated post-transaction holding value of about $2.81 million based on the same reference price. The transaction is a routine equity retainer grant rather than an open-market trade.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000083

Alert Tier

4